



2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: us.340B@gsk.com

October 1, 2024

FOR 340B COVERED ENTITIES THAT PURCHASE NUCALA, PLEASE NOTE THAT SENDERRA RX WILL NO LONGER DISPENSE NUCALA ON BEHALF OF THE GSK LIMITED PHARMACY NETWORK.

FOR 340B COVERED ENTITIES LOCATED IN MISSOURI, PLEASE NOTE AN UPDATE TO THE GSK 340B CONTRACT PHARMACY POLICY ON PAGE 2

FOR 340B COVERED ENTITIES LOCATED IN MINNESOTA, PLEASE NOTE AN UPDATE TO THE GSK 340B CONTRACT PHARMACY POLICY ON PAGE 3

FOR 340B COVERED ENTITIES LOCATED IN MISSISSIPPI, MARYLAND, OR KANSAS, PLEASE NOTE AN UPDATE TO THE GSK 340B CONTRACT PHARMACY POLICY ON PAGE 4

FOR 340B COVERED ENTITIES LOCATED IN WEST VIRGINIA, PLEASE NOTE AN UPDATE TO THE GSK 340B CONTRACT PHARMACY POLICY ON PAGE 5

FOR 340B COVERED ENTITIES LOCATED IN LOUISIANA OR ARKANSAS, PLEASE NOTE AN UPDATE TO THE GSK 340B CONTRACT PHARMACY POLICY ON PAGE 6



2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: us.340B@gsk.com

August 23, 2024

**Notice to 340B Covered Entities Located in Missouri - Update to GSK's 340B Contract Pharmacy Policy Effective August 28, 2024**

Dear Valued 340B Customer:

I am writing to inform you that GlaxoSmithKline (GSK) is updating its 340B Contract Pharmacy Policy that will alter its approach to distributing and accessing products purchased at the 340B price.

To ensure compliance with Missouri state law requirements (S.B. 751), GSK is implementing changes to its Contract Pharmacy Policy (effective since May 1, 2023).

Effective August 28, 2024, GSK will make the following modifications to its policy for 340B covered entities located in **Missouri**:

- **Missouri covered entities** will be able to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies located within Missouri.
- For GSK specialty/oncology products part of a limited pharmacy network, 340B covered entities located in Missouri will be able to place "Bill to/Ship to" replenishment orders through all their HRSA designated contract pharmacies part of GSK's limited pharmacy network (See network below).
- GSK will honor Bill To / Ship To replenishment orders for 340B covered entities located in Missouri associated with product dispensed on or after August 28, 2024.

GSK continues to monitor state level 340B contract pharmacy requirements and may make additional modifications to the above requirements, including re-instituting its May 1, 2023 Policy.

If you have questions regarding the changes to GSK's 340B Contract Pharmacy Policy, please contact GSK at [support@340Besp.com](mailto:support@340Besp.com).



2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: us.340B@gsk.com

July 26, 2024

**Notice to 340B Covered Entities Located in Minnesota - Update to GSK's 340B Contract Pharmacy Policy Effective August 1, 2024**

Dear Valued 340B Customer:

I am writing to inform you that GlaxoSmithKline (GSK) is updating its 340B Contract Pharmacy Policy that will alter its approach to distributing and accessing products purchased at the 340B price.

To ensure compliance with the newly-passed Minnesota state law requirements (HF 4757), GSK is implementing changes to its Contract Pharmacy Policy (effective since May 1, 2023).

Effective August 1, 2024, GSK will make the following modifications to its policy for 340B covered entities located in **Minnesota**:

- **Minnesota covered entities** will be able to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies located within Minnesota.
- For GSK specialty/oncology products part of a limited pharmacy network, 340B covered entities located in Minnesota will be able to place "Bill to/Ship to" replenishment orders through all their HRSA designated contract pharmacies part of GSK's limited pharmacy network (See network below).
- GSK will honor Bill To / Ship To replenishment orders for 340B covered entities located in Minnesota associated with product dispensed on or after August 1, 2024.

GSK continues to monitor state level 340B contract pharmacy requirements and may make additional modifications to the above requirements, including re-instituting its May 1, 2023 Policy.

If you have questions regarding the changes to GSK's 340B Contract Pharmacy Policy, please contact GSK at [support@340Besp.com](mailto:support@340Besp.com).



2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: us.340B@gsk.com

June 26, 2024

## **Notice to 340B Covered Entities Located in Mississippi, Maryland or Kansas- Update to GSK's 340B Contract Pharmacy Policy**

### **Update to GSK's 340B Contract Pharmacy Policy, Effective July 1, 2024**

Dear Valued 340B Customer:

I am writing to inform you that GlaxoSmithKline (GSK) is updating its 340B Contract Pharmacy Policy that will alter our approach to distributing and accessing products purchased at the 340B price.

To ensure compliance with the newly-passed state law requirements under Mississippi law (HB 728/SB 2145); Kansas law (SB 521); and Maryland law (HB 1056/SB 986), GSK is implementing changes to its Contract Pharmacy Policy that became effective May 1, 2023.

Effective July 1, 2024, GSK will make the following voluntary modifications to its policy for 340B covered entities located in **Mississippi (MS), Maryland (MD) or Kansas (KS)**:

- **Mississippi covered entities** will be able to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies located within Mississippi.
- **Maryland covered entities** will be able to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies located within Maryland.
- **Kansas covered entities** will be able to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies located within Kansas.
- For GSK specialty/oncology products part of a limited pharmacy network, 340B covered entities located in MS, MD or KS will be able to place "Bill to/Ship to" replenishment orders through all their HRSA designated contract pharmacies part of GSK's limited pharmacy network (See network below on page 5).
- GSK will honor Bill To / Ship To replenishment orders for 340B covered entities located in MS, MD or KS associated with product dispensed on or after July 1, 2024.

In all other states (excluding Arkansas, Louisiana, West Virginia, Mississippi, Maryland and Kansas), GSK will continue to apply the Policy which took effect on May 1, 2023.

GSK continues to monitor state level 340B contract pharmacy requirements and may make additional modifications to the above requirements, including re-instituting its May 1, 2023 Policy.

If you have questions regarding the changes to GSK's 340B Contract Pharmacy Policy, please contact GSK at [support@340Besp.com](mailto:support@340Besp.com).



2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: us.340B@gsk.com

June 3, 2024

**Notice to West Virginia 340B Covered Entities**

**Update to GSK's 340B Contract Pharmacy Policy, Effective June 6, 2024**

Dear Valued 340B Customer:

I am writing to inform you that GlaxoSmithKline (GSK) is updating its 340B Contract Pharmacy Policy that will alter our approach to distributing products purchased at the 340B price.

To ensure compliance with the 340B Program requirements under West Virginia Code §60A-8-6a., GSK is implementing changes to its 340B Program Integrity Initiative that became effective May 1, 2023.

Effective June 6, 2024, GSK will make the following modifications to its policy for covered entities in West Virginia:

- West Virginia-based covered entities will be able to place “Bill to/Ship to” replenishment orders through their HRSA designated contract pharmacies for products not part of a GSK limited pharmacy network.
- For GSK specialty/oncology products part of a limited pharmacy network, West Virginia-based covered entities will be able to place “Bill to/Ship to” replenishment orders through their HRSA designated contract pharmacies part of GSK's limited pharmacy network (See network below on page 5).
- GSK will honor West Virginia covered entities' “Bill to/Ship to” replenishment orders on or after June 6, 2024 associated with the above policy exceptions.

In all states except Arkansas, Louisiana and West Virginia, GSK will continue to apply the policy as announced to covered entities in April 2023, which took effect on May 1, 2023.

GSK continues to monitor state level 340B contract pharmacy requirements and may make additional modifications to the above requirements including re-instituting our May 1, 2023, policy.

If you have questions regarding the changes to its 340B contract pharmacy policy, please contact GSK at [support@340Besp.com](mailto:support@340Besp.com).



2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: us.340B@gsk.com

**Notice to Arkansas and Louisiana 340B Covered Entities- Update to GSK's 340B Contract Pharmacy Policy, Effective November 1, 2023**

Dear Valued 340B Customer:

I am writing to inform you that GlaxoSmithKline (GSK) is updating its 340B Contract Pharmacy Policy (the "Policy" or "340B Policy") that will alter our approach to how covered entities may use contract pharmacies in Arkansas and Louisiana.

To ensure compliance with the state-imposed requirements under Arkansas Act 1103 and Louisiana Act 358, GSK is implementing changes to its 340B Policy which became effective on May 1, 2023.

Effective November 1, 2023, GSK will make the following modifications to its Policy for covered entities and their respective contract pharmacies located in Arkansas or Louisiana:

- Arkansas-based covered entities will be able to place "Bill to/Ship to" replenishment orders through their HRSA/OPA designated contract pharmacies located within Arkansas. For GSK specialty/oncology products part of a limited pharmacy network, the HRSA/OPA designated contract pharmacies must be part of GSK's limited pharmacy network.
- Louisiana-based covered entities will be able to place "Bill to/Ship to" replenishment orders through their HRSA/OPA designated contract pharmacies located within Louisiana. For GSK specialty/oncology products part of a limited pharmacy network, the HRSA/OPA designated contract pharmacies must be part of GSK's limited pharmacy network.
- GSK will honor Arkansas- and Louisiana-based covered entities' "Bill to/Ship to" replenishment orders associated with a covered product dispensed within the respective state on or after August 1, 2023.

GSK continues to monitor federal and state level 340B contract pharmacy requirements and may make additional modifications to the above requirements, including re-instituting our May 1, 2023, Policy in Arkansas and/or Louisiana.

In all states except Arkansas and Louisiana, the GSK Policy of May 1, 2023, remains unchanged.

If you have questions regarding the changes to its 340B contract pharmacy policy, please contact GSK at [support@340Besp.com](mailto:support@340Besp.com).



2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: us.340B@gsk.com

### GSK Limited Pharmacy Networks (as of 1 October 2024)

GSK Limited Pharmacy Network	Benlysta	Nucala	Zejula	Flolan	Ojjaara
AcariaHealth, Inc.	X	X			
Accredo Health Group, Inc.	X	X	X	X	
AllianceRx Walgreens Pharmacy	X	X			
Amber Specialty Pharmacy	X				
Meijer Specialty Pharmacy	X				
Biologics, Inc.			X		X
Caremark, LLC	X	X	X	X	
CenterWell Pharmacy (f/k/a Humana Pharmacy, Inc.)	X	X			
Kroger Specialty Pharmacy Holdings, Inc.	X	X			
Magellan Rx Pharmacy, LLC	X				
Optum Rx	X	X	X		
Reliance Rx	X				
Senderra Rx	X				
Onc360					X

X indicates the GSK product eligible to be dispensed from the given pharmacy



2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: us.340B@gsk.com

## **GSK's 340B Contract Pharmacy Policy, Effective May 1, 2023**

Effective May 1, 2023, GSK implemented the following changes to its 340B Contract Pharmacy Policy.

- GSK's policy will apply to all GSK products contracted on the PHS contract (Vaccines and ViiV are excluded). A complete list of NDCs can be accessed by downloading GSK's policy document at [www.340Besp.com/resources](http://www.340Besp.com/resources).
- Federal Grantees are no longer exempt from the GSK 340B Contract Pharmacy Policy.
- Covered entities are no longer able to have unlimited contract pharmacies. GSK will no longer require the submission of 340B claims data or allow "bill to/ship to" replenishment orders for an unlimited number of contract pharmacies.
- To ensure 340B covered entities can access GSK products at the 340B price, any covered entity that does not have an in-house pharmacy capable of dispensing 340B purchased drugs to its patients may designate a single contract pharmacy location. For GSK specialty/oncology products that are part of a limited pharmacy network, the single contract pharmacy designation must be part of GSK's limited pharmacy network (locations listed below). Covered entities not able to dispense GSK specialty/oncology products will need to designate a single specialty pharmacy for each of GSK's limited pharmacy network products. GSK is utilizing the 340B ESP™ platform to support this designation.
- Contract pharmacies that are wholly owned by the covered entity (or have common ownership with the entity) will remain eligible to receive bill to/ship to replenishment orders of 340B priced drugs (inclusive of GSK products subject to a limited pharmacy network). These pharmacies must be registered with HRSA as a contract pharmacy. To apply for a wholly owned contract pharmacy exemption, please visit [www.340besp.com/wholly\\_owned\\_application](http://www.340besp.com/wholly_owned_application). Hospital Covered entities that have already been granted a GSK exception for their wholly owned contract pharmacies do not need to take any action.

340B covered entities that do not have an in-house pharmacy and haven't already registered an account with 340B ESP™ can make their designations by visiting [www.340besp.com/designations](http://www.340besp.com/designations). Users that have registered an account with 340B ESP™ can designate a contract pharmacy by navigating to the Entity Profile tab.

If you have questions regarding the changes to its 340B contract pharmacy policy, please contact GSK at [support@340Besp.com](mailto:support@340Besp.com).

Subject to the exceptions described above, PHS contracts administered by GSK's wholesalers/distributors will no longer support distribution of 340B purchased drugs to 340B contract pharmacies.

Best Regards,

The GSK 340B Team





2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: us.340B@gsk.com

## Frequently Asked Questions

GSK Policy of May 1, 2023, for all states except Arkansas and Louisiana.

### **Q: Which products are subject to GSK's policy?**

A: GSK's contract pharmacy policy applies to all of GSK's 340B contracted products. Covered entities may access the complete list of NDCs by downloading GSK's policy document at [www.340Besp.com/resources](http://www.340Besp.com/resources).

### **Q: Will GSK still allow covered entities to submit claims data for an unlimited number of contract pharmacies?**

A: No. GSK will no longer allow for an unlimited number of contract pharmacies. Claims data is no longer a requirement under GSK's policy nor will submission permit use of an unlimited number of contract pharmacy locations.

### **Q: Are Federal Grantees still exempt from GSK's policy?**

A: No. Federal Grantees are no longer exempt from GSK's 340B contract pharmacy product distribution policy.

### **Q: My covered entity has a contract pharmacy relationship with a pharmacy that is owned by the covered entity. Is this pharmacy subject to GSK's policy?**

A: No. Contract pharmacies that are wholly owned by the covered entity are not subject to GSK's policy. Covered entities can ship 340B purchased drugs to all of their wholly owned contract pharmacies without limitation. To apply for a wholly owned contract pharmacy exemption, visit [www.340besp.com/wholly\\_owned\\_application](http://www.340besp.com/wholly_owned_application). Covered entities that are granted a wholly owned contract pharmacy exception may not also designate a single contract pharmacy under GSK's 340B contract pharmacy policy. Hospital Covered entities that have already been granted a GSK exception for their wholly owned contract pharmacies do not need to take any action.

### **Q: My covered entity has an in-house pharmacy that is capable of purchasing and dispensing GSK drugs, but my entity doesn't use it to dispense GSK drugs. Can my covered entity designate one contract pharmacy instead?**

A: No. Under GSK's revised policy, if a covered entity has an in-house pharmacy capable of dispensing GSK's 340B products to eligible patients, then the covered entity must use that pharmacy and cannot designate a contract pharmacy instead.

### **Q: My covered entity has an in-house pharmacy that is not capable of purchasing and dispensing all of GSK 340B drugs. Can my entity designate a contract pharmacy to dispense GSK drugs that they are not capable of being dispensed in-house?**

A: Yes. Under GSK's policy, if a covered entity has an in-house pharmacy not capable of dispensing all of GSK's 340B products to eligible patients, then the covered entity may designate a contract pharmacy instead. In some instances, a covered entity may need to designate separate contract pharmacies for GSK products, subject to a limited pharmacy network. For example, if a covered entity cannot dispense specialty/oncology products at its in-house pharmacy but can dispense GSK retail products, this covered entity may designate a single contract pharmacy that is part of GSK's limited pharmacy network to dispense the specialty/oncology products. A complete list of GSK's limited pharmacy network is below. Hospital covered entities that have already designated a contract pharmacy for GSK retail products will not have to re-designate this pharmacy.



2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: us.340B@gsk.com

**Q. My 340B covered entity has contract pharmacy arrangements with multiple locations of the same pharmacy (e.g. six different Accredo pharmacy locations). Can my entity designate all locations of the same pharmacy?**

A. No. GSK's policy allows qualifying 340B covered entities (i.e., covered entities without an in-house pharmacy) to designate a single contract pharmacy location. Contract pharmacy locations are registered individually on the HRSA database and 340B covered entities are permitted to designate only a single contract pharmacy location which corresponds to a single contract pharmacy registration with HRSA. The only exceptions to the above are contract pharmacies wholly owned by a covered entity or that have common ownership with the covered entity.

**Q. How often can my covered entity change its contract pharmacy designation?**

A. Covered entities may change their contract pharmacy designation once every twelve (12) months (from the date of first designation) or more often if the designated contract pharmacy relationship is terminated from the HRSA OPAIS database.

**Q. How does my covered entity change its contract pharmacy designation?**

A. 340B covered entities can elect a single contract pharmacy every twelve (12) months. Changes to the single contract pharmacy can only be made by visiting [www.340Besp.com/designations](http://www.340Besp.com/designations). Users that have registered an account with 340B ESP™ can navigate to the Entity Profile tab to make their contract pharmacy designation.

**Q. Is GSK requiring covered entities to have a HIN registered for the contract pharmacy that they designate?**

A. Yes. A contract pharmacy must have a HIN assigned to it in order for a covered entity to designate it as its single contract pharmacy or to be approved for a wholly owned contract pharmacy exemption. This information is important for GSK to manage its process with its wholesalers.

**Q. If the contract pharmacy my covered entity wants to designate doesn't have a HIN, how does my entity get one?**

A. GSK will not register a HIN on your behalf, however if you need guidance or more information on how to get a HIN assigned to your contract pharmacy, please reach out to [support@340besp.com](mailto:support@340besp.com). If you try to designate a contract pharmacy without a HIN in 340B ESP™, the system will notify you of this requirement and provide instructions for how to obtain a HIN.

**Q. How long does it take for my covered entity's eligible contract pharmacy locations to take effect after May 1, 2023?**

A. Covered entities can take action to comply with GSK's policy after it goes into effect on May 1, 2023. After April 15, 2023, please allow a minimum of 10 business days for the eligible contract pharmacy locations to take effect.



2929 Walnut Street, Suite 1700  
 Philadelphia, PA 19104  
 Email: us.340B@gsk.com

### GSK Limited Pharmacy Network – (As of 1 October 2024) <sup>1</sup>

GSK Limited Pharmacy Network	Benlysta	Nucala	Zejula	Flolan	Ojjaara
AcariaHealth, Inc.	X	X			
Accredo Health Group, Inc.	X	X	X	X	
AllianceRx Walgreens Pharmacy	X	X			
Amber Specialty Pharmacy	X				
Meijer Specialty Pharmacy	X				
Biologics, Inc.			X		X
Caremark, LLC	X	X	X	X	
CenterWell Pharmacy (f/k/a Humana Pharmacy, Inc.)	X	X			
Kroger Specialty Pharmacy Holdings, Inc.	X	X			
Magellan Rx Pharmacy, LLC	X				
Optum Rx	X	X	X		
Reliance Rx	X				
Senderra Rx	X				
Onco360					X

X indicates the GSK product eligible to be dispensed from the given pharmacy

<sup>1</sup> Subject to change with notice. 340B covered entities that do not have an in-house pharmacy and haven't already registered an account with 340B ESP™ can make their designations by visiting [www.340besp.com/designations](http://www.340besp.com/designations). Users that have registered an account with 340B ESP™ can designate a contract pharmacy by navigating to the Entity Profile tab.



2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: us.340B@gsk.com

**GSK PHS NDC List**  
**As of October 1, 2024**

<b>NDC</b>	<b>Brand</b>	<b>Product Description</b>
00173-0695-04	ADVAIR DISKUS	ADVAIR DISKUS INH PWDR 100/50MCG 14D INS
00173-0695-00	ADVAIR DISKUS	ADVAIR DISKUS INH PWDR 100/50MCG 60 ACTN
00173-0696-04	ADVAIR DISKUS	ADVAIR DISKUS INH PWDR 250/50MCG 14D INS
00173-0696-00	ADVAIR DISKUS	ADVAIR DISKUS INH PWDR 250/50MCG 60 ACTN
00173-0697-04	ADVAIR DISKUS	ADVAIR DISKUS INH PWDR 500/50MCG 14D INS
00173-0697-00	ADVAIR DISKUS	ADVAIR DISKUS INH PWDR 500/50MCG 60 ACTN
00173-0716-20	ADVAIR HFA	ADVAIR HFA 115MCG/21MCG INH AER DC 120 ACTN TRD
00173-0716-22	ADVAIR HFA	ADVAIR HFA 115MCG/21MCG INH AER DC 60 ACTN INST
00173-0717-20	ADVAIR HFA	ADVAIR HFA 230MCG/21MCG INH AER DC 120 ACTN TRD
00173-0717-22	ADVAIR HFA	ADVAIR HFA 230MCG/21MCG INH AER DC 60 ACTN INST
00173-0715-20	ADVAIR HFA	ADVAIR HFA 45MCG/21MCG INH AER DC 120 ACTN TRD
00173-0715-22	ADVAIR HFA	ADVAIR HFA 45MCG/21MCG INH AER DC 60 ACTN INST
00173-0869-10	ANORO	ANORO ELLIPTA 62.5/25 MCG INH PWDR 1X30 DS
00173-0869-06	ANORO	ANORO ELLIPTA 62.5/25 MCG INH PWDR 1X7 DS INST
00173-0888-10	ARNUITY	ARNUITY (FF) ELLIPTA INH PWDR 50MCG 1X30 DOSE TRD
00173-0874-14	ARNUITY	ARNUITY ELLIPTA 100MCG DRY PWD INH 1X 14D INST
00173-0874-10	ARNUITY	ARNUITY ELLIPTA 100MCG DRY PWD INH 1X 30D TRD
00173-0876-14	ARNUITY	ARNUITY ELLIPTA 200MCG DRY PWD INH 1X 14D INST
00173-0876-10	ARNUITY	ARNUITY ELLIPTA 200MCG DRY PWD INH 1X 30D TRD
00173-0388-79	BECONASE	BECONASE AQ NSL SPR 0.042% 200D
49401-0102-01	BENLYSTA	BENLYSTA LYOPHILIZED 20ML VL (400MG/VL)1
49401-0101-01	BENLYSTA	BENLYSTA LYOPHILIZED 5ML VL (120MG/VL) 1
49401-0088-35	BENLYSTA	BENLYSTA SC 200MG/ML AUTOINJ 4S TRD CTN 4X1.0ML 1DS PF
49401-0088-47	BENLYSTA	BENLYSTA SC 200MG/ML SYRI 4S TRD CTN 4X1.0ML 1DS PF
00173-0859-14	BREO	BREO ELLIPTA 100/25 MCG INH PWDR 14 DOSE NDPI INST PAC X 1
00173-0859-10	BREO	BREO ELLIPTA 100/25 MCG INH PWDR 30 DS NDPI TRD PACK X 1
00173-0882-14	BREO	BREO ELLIPTA 200/25 MCG INH PWDR 1X 14D INST
00173-0882-10	BREO	BREO ELLIPTA 200/25 MCG INH PWDR 1X 30D
00173-0916-10	BREO	BREO ELLIPTA 50/25 MCG
00173-0662-00	EPIVIR	EPIVIR-HBV TABLETS 100MG 60'S
00173-0517-00	FLOLAN	FLOLAN INJ. 0.5MG/17ML VIAL 1'S
00173-0519-00	FLOLAN	FLOLAN INJ. 1.5MG/17ML VIAL 1'S
00173-0602-02	FLOVENT DISKUS	FLOVENT DISKUS 100MCG 60 ACTN 1S
00173-0601-02	FLOVENT DISKUS	FLOVENT DISKUS 250MCG 60 ACTN 1S
00173-0600-02	FLOVENT DISKUS	FLOVENT DISKUS 50MCG 60 ACTN 1'S
00173-0719-20	FLOVENT HFA	FLOVENT HFA 110MCG DC INH AER 120 ACT 1S
00173-0720-20	FLOVENT HFA	FLOVENT HFA 220MCG DC INH AER 120 ACT 1S
00173-0718-20	FLOVENT HFA	FLOVENT HFA 44MCG DC INH AER 120 ACTN 1S
00173-0739-02	IMITREX	IMITREX INJ STATDOSE REFILL 4MG/0.5ML 2S
00173-0478-00	IMITREX	IMITREX INJ STATDOSE REFILL 6MG/0.5ML 2S
00173-0739-00	IMITREX	IMITREX INJ STATDOSE SYSTEM 4MG/0.5ML 1S
00173-0479-00	IMITREX	IMITREX INJ STATDOSE SYSTEM 6MG/0.5ML 1S



2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: us.340B@gsk.com

NDC	Brand	Product Description
00173-0524-00	IMITREX	IMITREX NASAL SPRAY 5MG 6'S
00173-0737-01	IMITREX	IMITREX TAB 100MG 9'S FDT
00173-0735-00	IMITREX	IMITREX TAB 25MG 9S RRT
00173-0736-01	IMITREX	IMITREX TAB 50MG 9S RRT
00173-0873-10	INCRUSE	INCRUSE ELLIPTA INH PWDR 62.5MCG 1X30 DOSE TRD
00173-0873-06	INCRUSE	INCRUSE ELLIPTA INH PWDR 62.5MCG 1X7 DOSE INST
00173-0898-03	JEMPERLI	JEMPERLI IV, 500MG/10ML (50MG/ML) X1 SINGLE DOSE VIAL/CARTON
00173-0897-13	JESDUVROQ	JESDUVROQ TABLET 1MG 1X30
00173-0903-13	JESDUVROQ	JESDUVROQ TABLET 2MG 1X30
00173-0906-13	JESDUVROQ	JESDUVROQ TABLET 4MG 1X30
00173-0911-13	JESDUVROQ	JESDUVROQ TABLET 6MG 1X30
00173-0914-13	JESDUVROQ	JESDUVROQ TABLET 8MG 1X30
00173-0889-39	KRINTAFEL	KRINTAFEL TABLET 150MG 1X2
00173-0527-00	LAMICTAL	LAMICTAL CHW. DISP. TABLETS 25MG 100'S
00173-0526-00	LAMICTAL	LAMICTAL CHW. DISP. TABLETS 5MG 100'S
00173-0778-00	LAMICTAL ODT	LAMICTAL ODT 25MG/50MG/100MG STR KIT35S
00173-0779-00	LAMICTAL ODT	LAMICTAL ODT TABLET 25MG/50MG ST KIT 28S
00173-0780-00	LAMICTAL ODT	LAMICTAL ODT TABLET 50MG/100MG ST KIT56S
00173-0776-02	LAMICTAL ODT	LAMICTAL ODT TABLETS 100MG MAINT 30'S
00173-0777-02	LAMICTAL ODT	LAMICTAL ODT TABLETS 200MG MAINT 30'S
00173-0772-02	LAMICTAL ODT	LAMICTAL ODT TABLETS 25MG MAINT 30'S
00173-0774-02	LAMICTAL ODT	LAMICTAL ODT TABLETS 50MG MAINT 30'S
00173-0633-10	LAMICTAL	LAMICTAL TAB 25MG DOSE ESCALATION PACK
00173-0642-55	LAMICTAL	LAMICTAL TABLETS 100MG 100'S
00173-0643-60	LAMICTAL	LAMICTAL TABLETS 150MG 60'S
00173-0644-60	LAMICTAL	LAMICTAL TABLETS 200MG 60'S
00173-0817-28	LAMICTAL	LAMICTAL TABLETS 25MG & 100MG STARTER KIT
00173-0633-02	LAMICTAL	LAMICTAL TABLETS 25MG 100'S
00173-0594-02	LAMICTAL	LAMICTAL TABLETS 25MG/100MG BIPOLAR STARTER KIT
00173-0756-00	LAMICTAL XR	LAMICTAL XR TABLETS 100MG 30'S
00173-0757-00	LAMICTAL XR	LAMICTAL XR TABLETS 200MG 30'S
00173-0781-00	LAMICTAL XR	LAMICTAL XR TABLETS 250MG 30'S
00173-0754-00	LAMICTAL XR	LAMICTAL XR TABLETS 25MG 30'S
00173-0758-00	LAMICTAL XR	LAMICTAL XR TABLETS 25MG/50MG STARTER KT
00173-0760-00	LAMICTAL XR	LAMICTAL XR TABLETS 25MG/50MG/100MG KIT
00173-0761-00	LAMICTAL XR	LAMICTAL XR TABLETS 300MG 30'S BOTTLE
00173-0755-00	LAMICTAL XR	LAMICTAL XR TABLETS 50MG 30'S
00173-0759-00	LAMICTAL XR	LAMICTAL XR TABLETS 50MG/100MG/200MG KIT
00173-0676-01	MALARONE	MALARONE PED. TABLETS 62.5MG/25MG 100'S
00173-0675-01	MALARONE	MALARONE TABLETS 250MG/100MG 100'S
00173-0675-02	MALARONE	MALARONE TABLETS 250MG/100MG UD 24'S
00173-0547-00	MEPRON	MEPRON SUSP UD 5ML 42'S
00173-0665-18	MEPRON	MEPRON SUSPENSION 750MG/5ML 210ML



2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: us.340B@gsk.com

NDC	Brand	Product Description
00173-0881-01	NUCALA LYO	NUCALA (MEPOLIZUMAB) INJ 100MG 1 VIAL/CARTON
00173-0892-01	NUCALA SA	NUCALA SOLUTION INJECT AI 100MG/ML 1X1ML
00173-0892-42	NUCALA SA	NUCALA SOLUTION INJECT SS 100MG/ML 1X1ML
00173-0904-42	NUCALA SA	NUCALA SOLUTION INJECT SS 40MG/0.4ML 1X1
81864-0102-30	OJJAARA	OJJAARA TABLET 150MG 1X 30
81864-0101-30	OJJAARA	OJJAARA TABLET 200MG 1X 30
81864-0103-30	OJJAARA	OJJAARA TABLET 100MG 1X 30
00173-0681-01	RELENZA	RELENZA DISKHLR & 5X4 ROTADISKS 5MG 1'S
00173-0823-18	RYTHMOL	RYTHMOL SR CPSL 225MG 60SBOTTLE
00173-0824-18	RYTHMOL	RYTHMOL SR CPSL 325MG 60S BOTTLE
00173-0826-18	RYTHMOL	RYTHMOL SR CPSL 425MG 60SBOTTLE
00173-0521-00	SEREVENT DISKUS	SEREVENT DISKUS 50MCG/ACTN 60 ACTN 1'S
00173-0887-10	TRELEGY	TRELEGY ELLIPTA 1X30D TRD 100/62.5/25MCG PK/CA
00173-0893-14	TRELEGY	TRELEGY ELLIPTA 200/62.5/25MCG 1X14D INST PACK
00173-0893-10	TRELEGY	TRELEGY ELLIPTA 200/62.5/25MCG 1X30D TRADE PACK
00173-0887-14	TRELEGY	TRELEGY ELLIPTA INH PWDR 100/62.5/25MCG 1X14 DOSE INST
00173-0565-04	VALTREX	VALTREX CAPLETS 1G 30'S
00173-0565-10	VALTREX	VALTREX CAPLETS 1GM 90'S
00173-0933-08	VALTREX	VALTREX CAPLETS 500MG 30'S
00173-0933-10	VALTREX	VALTREX CAPLETS 500MG 90'S
00173-0682-24	VENTOLIN	VENTOLIN HFA 90MCG INH AER 60 ACTN
00173-0682-20	VENTOLIN	VENTOLIN HFA DC INH.AER. 18G 200INHL 1S
00173-0947-55	WELLBUTRIN	WELLBUTRIN SR TABLETS 100MG 60'S
00173-0135-55	WELLBUTRIN	WELLBUTRIN SR TABLETS 150MG 60'S
00173-0722-00	WELLBUTRIN	WELLBUTRIN SR TABLETS 200MG 60'S
00173-0909-13	ZEJULA	ZEJULA TABLET 100MG 1X30
00173-0912-13	ZEJULA	ZEJULA TABLET 200MG 1X30
00173-0915-13	ZEJULA	ZEJULA TABLET 300MG 1X30